Abstract

You have accessJournal of UrologyProstate Cancer: Localized: Surgical Therapy I1 Apr 2017PD10-01 OUTCOMES OF FLUORESCENCE SUPPORTED LYMPH NODE DISSECTION IN ROBOT-ASSISTED RADICAL PROSTATECTOMY – A PROSPECTIVE RANDOMIZED CLINICAL TRIAL Nina Harke, Christian Wagner, Katarina Urbanova, Michael Godes, Mustapha Addali, Bernhard Fangmeyer, Andreas Schuette, and Jorn H. Witt Nina HarkeNina Harke More articles by this author , Christian WagnerChristian Wagner More articles by this author , Katarina UrbanovaKatarina Urbanova More articles by this author , Michael GodesMichael Godes More articles by this author , Mustapha AddaliMustapha Addali More articles by this author , Bernhard FangmeyerBernhard Fangmeyer More articles by this author , Andreas SchuetteAndreas Schuette More articles by this author , and Jorn H. WittJorn H. Witt More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.564AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The detection of lymph node metastases has a major impact on patients with prostate cancer. However, there is still a debate on the extent of pelvic lymphadenectomy, the usage of near-infrared fluorescence (NIRF) and sentinel node dissection in radical prostatectomy. This study aims to demonstrate the outcomes of NIRF lymph node dissection in robot-assisted radical prostatectomy. METHODS 120 patients with intermediate (72%) or high risk (28%) prostate cancer were prospectively randomized (1:1): in the intervention group indocyanine green (ICG) was injected transrectally into the prostate before docking of the robot. In both groups an extended pelvic lymph node dissection (ePLND) was performed including eventual dissection of fluorescent lymph nodes (LN) in the ICG group. RESULTS After exclusion of two drop-outs, 59 patients were allocated in the control (A) and intervention group (B) with a median PSA of 8,6 ng/ml. Median console time was 159 (A) vs. 168 (B) minutes (p=0,20) with a longer time for NIRF ePLND: 43 (A) vs. 55 minutes (B) (p=0,001). Overall, 2609 LN (median 22 LN) were found. In the ICG group 582 fluorescent LN were identified, while 899 were non-fluorescent. Significantly more LN could be harvested in B with median 25 LN vs. 17 in A (p<0,001). In 6 of the 59 patients in the intervention group, 19 additional fluorescent LN were found outside of the routine ePLND field. 15 out of 118 patients presented 87 nodal metastases. These metastases were detected in 6 patients in A (25 cancerous LN) vs. 9 patients in B (62 positive LN) (p=0,40). In 7 of 9 patients, NIRF ePLND identified at least one cancer-positive LN (sensitivity 78%), although 35 of 62 cancerous LN were non-fluorescent. No adverse reactions to ICG, no significant differences in complication rates (p=0,15); lymphocele occurred in one patient in A and in three patients in B (p=0,62). After six months, 5,8% vs. 3,7% showed a PSA>0,2 ng/ml (p=0,37) with a median PSA of 0,01 ng/ml in both groups (p=0,96). There was no difference in adjuvant therapy with 10 patients undergoing radiation therapy, 7 patients with androgen deprivation therapy (ADT) and 3 patients with combined radiation and ADT (p=0,78). CONCLUSIONS Without increased risk for the patient, NIRF ePLND leads to a significantly higher yield of lymph nodes. While it therefore seems to be beneficial with regard to a better understanding of the lymphatic drainage and a more meticulous diagnostic approach, the sensitivity seems not to be sufficient to recommend stand-alone NIRF sentinel lymph node dissection. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e199 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Nina Harke More articles by this author Christian Wagner More articles by this author Katarina Urbanova More articles by this author Michael Godes More articles by this author Mustapha Addali More articles by this author Bernhard Fangmeyer More articles by this author Andreas Schuette More articles by this author Jorn H. Witt More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.